CoChat

Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients

Open access
Chiappini, Franck, Coilly, Audrey, Kadar, Hanane, Gual, Philippe, Tran, Albert, Desterke, Christophe, Samuel, Didier, Duclos-Vallée, Jean-Charles, Touboul, David, Bertrand-Michel, Justine, Brunelle, Alain, Guettier, Catherine, Le Naour, François · 2017 · Scientific Reports

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Abstract

Nonalcoholic steatohepatitis (NASH) is a condition which can progress to cirrhosis and hepatocellular carcinoma. Markers for NASH diagnosis are still lacking. We performed a comprehensive lipidomic analysis on human liver biopsies including normal liver, nonalcoholic fatty liver and NASH. Random forests-based machine learning approach allowed characterizing a signature of 32 lipids discriminating NASH with 100% sensitivity and specificity. Furthermore, we validated this signature in an independent group of NASH patients. Then, metabolism dysregulations were investigated in both patients and murine models. Alterations of elongase and desaturase activities were observed along the fatty acid synthesis pathway. The decreased activity of the desaturase FADS1 appeared as a bottleneck, leading upstream to an accumulation of fatty acids and downstream to a deficiency of long-chain fatty acids resulting to impaired phospholipid synthesis. In NASH, mass spectrometry imaging on tissue section revealed the spreading into the hepatic parenchyma of selectively accumulated fatty acids. Such lipids constituted a highly toxic mixture to human hepatocytes. In conclusion, this study characterized a specific and sensitive lipid signature of NASH and positioned FADS1 as a significant player in accumulating toxic lipids during NASH progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep46658

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Selected lipids using random forests analysis discriminate NASH patients. (a) Data are represented as a bar plot of a matrix with 104 lipids (column) analyzed by mass spectrometry and ordered based on their variable of importance score. The threshold in the x-axis is calculated as the absolute value of the less abundant lipid represented as vertical red dot line. Discriminant lipids (n = 32) are those over the horizontal red dot line. Random forests analysis was run with the 5 groups of patients. (b) Multidimensional scaling plot discriminating NASH_Lds group from Control, NAFL1, NAFL2 and NAFL3 groups based on random forests results. (c) Principal component analysis based on the 32 lipids identified discriminating specifically NASH patients (NASH_Lds). Lines are the ellipses centered to the mean (colored squares) representing 95% interval confidence, and p the probability associated with the F- test of the analysis of variance along the axes. ROC curves based on the 32 lipids combined comparing (d) NAFLD groups of patients (i.e. Control + NAFL1 + NAFL + NAFL3) and NASH group (NASH_Lds) from Paul Brousse Hospital, and (e) NASH group (NASH_Vds) from L’cc. • Control n = 7; NAFL1 n = 9; NAFL2 n = 12; NAFL3 n = 18; NASH_Lds n = 15, NASH_Vds n = 7. AUC: Area under the curve; CE: cholesteryl ester; Cer: Ceramides; DG: diacylglycerols; NAFL: nonalcoholic fatty liver; NASH: nonalcoholic steatohepatitis; PC: Phosphatidylcholines; PE: Phosphatidylethanolamines; PI: Phosphatidylinositols; PS: Phosphatidylserines; PV: predictive value; SM: Sphingomyelins, TG: triglycerides.
Figure 1 Selected lipids using random forests analysis discriminate NASH patients. (a) Data are represented as a bar plot of a matrix with 104 lipids (column) analyzed by mass spectrometry and ordered based on their variable of importance score. The threshold in the x-axis is calculated as the absolute value of the less abundant lipid represented as vertical red dot line. Discriminant lipids (n = 32) are those over the horizontal red dot line. Random forests analysis was run with the 5 groups of patients. (b) Multidimensional scaling plot discriminating NASH_Lds group from Control, NAFL1, NAFL2 and NAFL3 groups based on random forests results. (c) Principal component analysis based on the 32 lipids identified discriminating specifically NASH patients (NASH_Lds). Lines are the ellipses centered to the mean (colored squares) representing 95% interval confidence, and p the probability associated with the F- test of the analysis of variance along the axes. ROC curves based on the 32 lipids combined comparing (d) NAFLD groups of patients (i.e. Control + NAFL1 + NAFL + NAFL3) and NASH group (NASH_Lds) from Paul Brousse Hospital, and (e) NASH group (NASH_Vds) from L’cc. • Control n = 7; NAFL1 n = 9; NAFL2 n = 12; NAFL3 n = 18; NASH_Lds n = 15, NASH_Vds n = 7. AUC: Area under the curve; CE: cholesteryl ester; Cer: Ceramides; DG: diacylglycerols; NAFL: nonalcoholic fatty liver; NASH: nonalcoholic steatohepatitis; PC: Phosphatidylcholines; PE: Phosphatidylethanolamines; PI: Phosphatidylinositols; PS: Phosphatidylserines; PV: predictive value; SM: Sphingomyelins, TG: triglycerides.CC BY · PubMed Central
Figure 2 Hepatic levels of the 32 lipids discriminating NASH group based on random forests analysis. Data are represented as boxplot. *p < 0.05, by unpaired t-test compared to Control, NAFL1, NAFL2 and NAFL3 groups. +p < 0.05 by unpaired t-test compared to Control, NAFL1 and NAFL2 groups. §p < 0.05 by unpaired t-test compared to Control group. Unpaired t-test was done after ANOVA test. ■ Control n = 7; NAFL1 n = 9; NAFL2 n = 12; NAFL3 n = 18; NASH_Lds n = 15; NASH_Vds n = 7. NAFL: nonalcoholic fatty liver; NASH: nonalcoholic steatohepatitis; NASH_Lds: learning dataset; NASH_Vds: validation dataset.
Figure 2 Hepatic levels of the 32 lipids discriminating NASH group based on random forests analysis. Data are represented as boxplot. *p < 0.05, by unpaired t-test compared to Control, NAFL1, NAFL2 and NAFL3 groups. +p < 0.05 by unpaired t-test compared to Control, NAFL1 and NAFL2 groups. §p < 0.05 by unpaired t-test compared to Control group. Unpaired t-test was done after ANOVA test. ■ Control n = 7; NAFL1 n = 9; NAFL2 n = 12; NAFL3 n = 18; NASH_Lds n = 15; NASH_Vds n = 7. NAFL: nonalcoholic fatty liver; NASH: nonalcoholic steatohepatitis; NASH_Lds: learning dataset; NASH_Vds: validation dataset.CC BY · PubMed Central
Figure 3 Scheme of short-, long- and very long-chain fatty acid biosynthesis leading to membrane phospholipids synthesis. The long chain saturated fatty acids and unsaturated fatty acids of the n-3, n-6, n-7 and n-9 series can be synthesized from myristic acid (C14:0) and palmitic acid (C16:0) produced by ACC and FASN. Long-chain fatty acids of the n-6 and n-3 series can also be synthesized from precursors obtained from dietary precursors to elongation (ELOVL) and desaturation (FADS) steps as indicated in these pathways. Lipids in red and in green are those found “up” and “down” in our analysis, respectively. Increase in enzyme activities is framed in red whereas a decrease is framed in green. ACC: acetyl-CoA carboxylase; ELOVL: elongase of very long chain fatty acid; FASN: fatty acid synthase; FADS: fatty acid desaturase; SCD: stearoyl-CoA desaturase.
Figure 3 Scheme of short-, long- and very long-chain fatty acid biosynthesis leading to membrane phospholipids synthesis. The long chain saturated fatty acids and unsaturated fatty acids of the n-3, n-6, n-7 and n-9 series can be synthesized from myristic acid (C14:0) and palmitic acid (C16:0) produced by ACC and FASN. Long-chain fatty acids of the n-6 and n-3 series can also be synthesized from precursors obtained from dietary precursors to elongation (ELOVL) and desaturation (FADS) steps as indicated in these pathways. Lipids in red and in green are those found “up” and “down” in our analysis, respectively. Increase in enzyme activities is framed in red whereas a decrease is framed in green. ACC: acetyl-CoA carboxylase; ELOVL: elongase of very long chain fatty acid; FASN: fatty acid synthase; FADS: fatty acid desaturase; SCD: stearoyl-CoA desaturase.CC BY · PubMed Central
Figure 4 Decrease in ELOVL 6 and FADS1 activities in NASH patients and mouse feeding a methionine-choline deficient diet. In order to evaluate enzyme activities, ratio between product to precursor of each reaction has been used in human groups (left panel) and mouse models (right panel). (a) Evaluation of ELOVL5 activity using C20:2n-6 to C18:2n-6 ratio, (b) ELOVL6 activity using C18:0 to C16:0 ratio, (c) FADS2 activity using C18:3n-3 to C18:2n-6 ratio, (d) SCD1 activity using C16:1 to C16:0 ratio and (e) FADS1 activity using C20:4n-6 to C20:3n-6 ratio. Data are shown as mean ± SEM. *p < 0.05 by unpaired t-test compared to each other groups. +<0.05 by unpaired t-test compared to Control and §p < 0.05 by unpaired t-test compared to Control. NAFL1 and NAFL2 after ANOVA analysis. Control patients n = 7; NAFL1 n = 9; NAFL2 n = 12; NAFL3 n = 18; NASH_Lds n = 15; NASH_Vds n = 7. Control mice n = 10; HFD n = 5; MCDD n = 5.
Figure 4 Decrease in ELOVL 6 and FADS1 activities in NASH patients and mouse feeding a methionine-choline deficient diet. In order to evaluate enzyme activities, ratio between product to precursor of each reaction has been used in human groups (left panel) and mouse models (right panel). (a) Evaluation of ELOVL5 activity using C20:2n-6 to C18:2n-6 ratio, (b) ELOVL6 activity using C18:0 to C16:0 ratio, (c) FADS2 activity using C18:3n-3 to C18:2n-6 ratio, (d) SCD1 activity using C16:1 to C16:0 ratio and (e) FADS1 activity using C20:4n-6 to C20:3n-6 ratio. Data are shown as mean ± SEM. *p < 0.05 by unpaired t-test compared to each other groups. +<0.05 by unpaired t-test compared to Control and §p < 0.05 by unpaired t-test compared to Control. NAFL1 and NAFL2 after ANOVA analysis. Control patients n = 7; NAFL1 n = 9; NAFL2 n = 12; NAFL3 n = 18; NASH_Lds n = 15; NASH_Vds n = 7. Control mice n = 10; HFD n = 5; MCDD n = 5.CC BY · PubMed Central
Figure 5 Decrease in eicosanoid precursors in NASH. Hepatic levels of (a) arachidonic acid (C20:4n-6), eicosapentanoic acid (C20:5n-3), and docosahexaenoic acid (C22:6n-3) in the patients studied (upper panel) and mouse models (lower panel). (b) Total phospholipids in each group of patients. Data are means ± SEM. *p < 0.05, by unpaired t-test compared to Control group and †p < 0.05, by unpaired t-test compared to NAFL groups after ANOVA analysis. Control n = 7; NAFL1 n = 9; NAFL2 n = 12; NAFL3 n = 18; NASH_Lds n = 15; NASH_Vds n = 7 and Control n = 10; HFD n = 5; MCDD n = 5.
Figure 5 Decrease in eicosanoid precursors in NASH. Hepatic levels of (a) arachidonic acid (C20:4n-6), eicosapentanoic acid (C20:5n-3), and docosahexaenoic acid (C22:6n-3) in the patients studied (upper panel) and mouse models (lower panel). (b) Total phospholipids in each group of patients. Data are means ± SEM. *p < 0.05, by unpaired t-test compared to Control group and †p < 0.05, by unpaired t-test compared to NAFL groups after ANOVA analysis. Control n = 7; NAFL1 n = 9; NAFL2 n = 12; NAFL3 n = 18; NASH_Lds n = 15; NASH_Vds n = 7 and Control n = 10; HFD n = 5; MCDD n = 5.CC BY · PubMed Central
Figure 6 Membrane integrity is disrupted in NASH patients and mice leading to release of lipids in parenchyma. (a) Phosphatidylcholine (PC) to phosphatidylethanolamine (PE) ratio in the patients studied (left panel) and mouse models (right panel). (b) Myristic acid (C14:0) and (c) sum of all diacylglycerols (DG) liver contents in NAFL3 and NASH patients. Both selected patches regarding myristic acid were matched according to the total count (TC). Each patch is representative of the 6–12 patches recorded from central vein to portal triad. Between 2 to 3 slices per sample were processed. Color scale bar with amplitude in number of counts are indicated to the right of each image. Field of view of 500 μm × 500 μm. Scale bars: 100 μm. Data are means ± SEM. *p < 0.05 by unpaired t-test compared to Control group and †p < 0.05 by unpaired t-test compared to NAFL groups after ANOVA analysis. Control n = 7; NAFL1 n = 9; NAFL2 n = 12; NAFL3 n = 18; NASH_Lds n = 15, NASH_Vds n = 7 and Control n = 20; HFD n = 5; MCDD n = 5 mouse males. (d) HepG2 cell and (e) human primary hepatocytes treated with lipid mixes at different concentrations. Cells are treated in triplicate during 24 h with 50. 100. 250. 500 and 1000 μM final concentration of lipids with lipid mixes (Control Mix. NAFLD Mix. NASH Mix) based on the percentage of C14:0, C16:0, C16:1n-7, C18:1n-7, and C18:1n-9 found in liver tissues of control. NAFL2/3 and NASH patients. Two independent experiments were done. Data are mean ± SEM. +p < 0.05 by unpaired t-test compared to Control Mix and NAFL Mix at the same concentrations after ANOVA test.
Figure 6 Membrane integrity is disrupted in NASH patients and mice leading to release of lipids in parenchyma. (a) Phosphatidylcholine (PC) to phosphatidylethanolamine (PE) ratio in the patients studied (left panel) and mouse models (right panel). (b) Myristic acid (C14:0) and (c) sum of all diacylglycerols (DG) liver contents in NAFL3 and NASH patients. Both selected patches regarding myristic acid were matched according to the total count (TC). Each patch is representative of the 6–12 patches recorded from central vein to portal triad. Between 2 to 3 slices per sample were processed. Color scale bar with amplitude in number of counts are indicated to the right of each image. Field of view of 500 μm × 500 μm. Scale bars: 100 μm. Data are means ± SEM. *p < 0.05 by unpaired t-test compared to Control group and †p < 0.05 by unpaired t-test compared to NAFL groups after ANOVA analysis. Control n = 7; NAFL1 n = 9; NAFL2 n = 12; NAFL3 n = 18; NASH_Lds n = 15, NASH_Vds n = 7 and Control n = 20; HFD n = 5; MCDD n = 5 mouse males. (d) HepG2 cell and (e) human primary hepatocytes treated with lipid mixes at different concentrations. Cells are treated in triplicate during 24 h with 50. 100. 250. 500 and 1000 μM final concentration of lipids with lipid mixes (Control Mix. NAFLD Mix. NASH Mix) based on the percentage of C14:0, C16:0, C16:1n-7, C18:1n-7, and C18:1n-9 found in liver tissues of control. NAFL2/3 and NASH patients. Two independent experiments were done. Data are mean ± SEM. +p < 0.05 by unpaired t-test compared to Control Mix and NAFL Mix at the same concentrations after ANOVA test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Cited by

Metadata

Authors
Chiappini, F., Coilly, A., Kadar, H., Gual, P., Tran, A., Desterke, C., Samuel, D., Duclos-Vallée, J.-C., Touboul, D., Bertrand-Michel, J., Brunelle, A., Guettier, C., & Le Naour, F.
Affiliations
  • Université Paris-Sud (FR)
  • Inserm (FR)
Corresponding author
Chiappini, Franck
Venue
Scientific Reports
Published
2017-04-24
Volume
7
Issue
1
Pages
46658-46658
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2609371482
Cited by
246
References
71
Citations by year
2026: 16 · 2025: 31 · 2024: 35 · 2023: 37 · 2022: 27 · 2021: 36 · 2020: 28 · 2019: 19 · 2018: 14 · 2017: 2
FWCI
13.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • HAL (submittedVersion)
Funders
  • Agence Nationale de la Recherche (ANR-11-INBS, ANR-10, ANR-10-LABX, ANR-10-LABX-0033, ANR-11-INBS-0010)
  • Institut National de la Santé et de la Recherche Médicale
  • Fondation pour la Recherche Médicale (SPF20111223621)
  • Centre National de la Recherche Scientifique (ANR-11-INBS-0010)
  • Centre Hospitalier Universitaire de Nice
  • Université Paris-Sud
  • Laboratoire d'Excellence en Recherche sur le Médicament et l'Innovation Thérapeutique
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
Keywords
nonalcoholic steatohepatitis, lipidomics, lipid signatures, FADS1, fatty acid desaturase, fatty acid synthesis, fatty acid accumulation, phospholipid synthesis, hepatocyte cytotoxicity, non-alcoholic fatty liver disease, liver biopsy, mass spectrometry imaging, metabolic dysfunction, NASH diagnosis
MeSH terms
Fatty Acid Elongases, Delta-5 Fatty Acid Desaturase, Acetyltransferases, Adult, Animals, Cells, Cultured, Fatty Acids, Female, Carcinoma, Hepatocellular, Humans, Lipids, Liver Cirrhosis, Liver Neoplasms, Male, Mice, Inbred C57BL, Middle Aged, Disease Progression, Hepatocytes, Fatty Acid Desaturases, Lipid Metabolism, Metabolomics, Hep G2 Cells, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.